Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Declining or stable rates of most AEs support an acceptable long-term safety profile for axitinib in patients with mRCC. However, increases in the rates of some AEs warrant monitoring. This analysis is limited in that it was retrospective and included a relatively small patient population.